Irbesartan/Hydroklortiazid Actavis

Irbesartan, the active ingredient in Irbesartan/Hydrochlorothiazide Actavis, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension in adults, often combined with hydrochlorothiazide to enhance blood‑pressure control.

GNH USA supplies Irbesartan/Hydrochlorothiazide Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is an antihypertensive combination that acts on the renin‑angiotensin system and renal sodium handling to lower blood pressure.

Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension. Hypertension requiring combined ARB and diuretic therapy: provides dual mechanism for improved control when monotherapy is insufficient. Resistant hypertension: used as part of a multi‑drug regimen for patients whose blood pressure remains elevated despite other treatments.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache. - Increased frequency of urination. - Fatigue or mild weakness. - Electrolyte disturbances such as low potassium. - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance. - Acute kidney injury or worsening renal function. - Hyperkalemia, especially when used with potassium‑sparing agents. - Angioedema or severe allergic reaction. - Significant drops in blood pressure (hypotension). - Blood dyscrasias such as agranulocytosis or thrombocytopenia.

Before initiating therapy, clinicians should assess baseline blood pressure, renal function, and electrolyte status.

Monitor blood pressure regularly: adjust therapy based on response. Check renal function: evaluate serum creatinine and eGFR before and during treatment. Assess electrolytes: especially potassium and sodium levels. Avoid use in severe renal impairment: contraindicated when creatinine clearance is markedly reduced. Use caution in elderly patients: increased sensitivity to hypotension and electrolyte shifts. Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - ACE inhibitors or aliskiren in pregnancy: risk of angioedema and renal dysfunction. - Potassium‑sparing diuretics or supplements: can cause dangerous hyperkalemia. - Lithium: increased lithium levels and toxicity. - NSAIDs: may blunt antihypertensive effect and impair renal function. - Cyclosporine or tacrolimus: heightened risk of nephrotoxicity.

Moderate Interactions (Monitor Closely): - Other antihypertensives (beta‑blockers, calcium channel blockers): may enhance hypotensive effect. - Additional thiazide or loop diuretics: increase risk of electrolyte disturbances. - Antidiabetic agents: diuretic‑induced changes in glucose may require dose adjustment. - CYP2C9 inhibitors (e.g., fluconazole): may raise irbesartan plasma levels. - Antacids containing aluminum or magnesium: may affect absorption of hydrochlorothiazide.